Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR342434 versus Humalog in adults with type 2 diabetes using insulin glargine
2014-002844-42Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin lispro (Wockhardt), human insulin and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Change in HbA1c from baseline. Started Dec 2014; status: completed.
02
Drugs
insulin lispro (Wockhardt)human insulininsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2014-002844-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002844-42.